Plain-English translation of NCT06955156 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new medication designed to protect your bone marrow while you receive chemotherapy and immunotherapy for triple-negative breast cancer. Chemotherapy often damages bone marrow, which can cause serious side effects like infections, bleeding, and severe fatigue. Researchers believe this medication might prevent that damage and allow you to tolerate stronger, more effective cancer treatment.
Chemotherapy damages the bone marrow's ability to make blood cells, which leads to dangerous infections, bleeding problems, and exhaustion—and sometimes forces doctors to lower doses or delay treatment. This trial is testing whether the medication can protect bone marrow cells during chemotherapy, allowing you to receive full-strength treatment without these harmful side effects.
You would receive a combination of three treatments given intravenously: (the protective medication), an anti-PD-1 immunotherapy drug, and chemotherapy drugs (paclitaxel and carboplatin). You would likely visit the treatment center regularly over several months to receive these medications before surgery. Blood tests and imaging scans would monitor how well the cancer responds and how your bone marrow is doing.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China